Inhibition of cancer angiogenesis using triptolide nanoparticles

Journal of Biomedical Nanotechnology

Volumn 11, Issue 5, 2015, Pages 805-815

  Wang, Cheng ^a   Shan, Ying ^a   Yang, Jiuli ^b   Xu, Xuelian ^a   Zhuang, Bo ^a   Fan, Yingfang ^a   Xu, Wei ^b  

^a OCEAN UNIVERSITY OF CHINA   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis inhibitor; Melanoma; Micelle; Triptolide; VEGF

Indexed keywords

DERMATOLOGY; DRUG PRODUCTS; ENCAPSULATION; ENDOTHELIAL CELLS; MICELLES; ONCOLOGY; POLYETHYLENE GLYCOLS;

ANGIOGENESIS INHIBITORS; ENCAPSULATION EFFICIENCY; MELANOMA; METHOXYPOLYETHYLENE GLYCOL; POLY (EPSILONCAPROLACTONE); TRIPTOLIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

TUMORS;

ALANINE AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; MACROGOL; NANOPARTICLE; POLYCAPROLACTONE; TRIPTOLIDE; VASCULOTROPIN; ALKYLATING AGENT; DITERPENE; DRUG CARRIER; EPOXIDE; PHENANTHRENE DERIVATIVE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL DIAMETER; CANCER INCIDENCE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; MALE; MELANOMA B16; MICELLE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; POLYMERIZATION; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; SUSTAINED DRUG RELEASE; TISSUE DISTRIBUTION; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CELL CULTURE; MELANOMA, EXPERIMENTAL; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELLS, CULTURED; DITERPENES; DRUG CARRIERS; EPOXY COMPOUNDS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHENANTHRENES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84918531694     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.2016     Document Type: Article

References (39)

1. C. Hwang and E. I. Heath, Angiogenesis inhibitors in the treatment of prostate cancer. J. Hematol. Oncol. 3, 26 (2010).
2. A. Abdollahi and J. Folkman, Evading tumor evasion: Current concepts and perspectives of anti-angioenic cancer therapy. Drug Resistance Update 13, 16 (2010).
3. S. Takano, Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathol 29, 73 (2012).
4. R. Rahman, S. Smith, C. Rahman, and R. Grundy, Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J. Oncol. 2010, 251231 (2010).
5. J. X. Ma, Y. L. Sun, Y. Q. Wang, H. Y. Wu, J. Jin, and X. F. Yu, Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF. Oncol. Res. 20, 359 (2013).
6. M. F. He, Y. H. Huang, L. W. Wu, W. Ge, P. C. Shaw, and P. P. But, Triptolide functions as a potent angiogenesis inhibitor. Int. J. Cancer 126, 266 (2010).
7. H. Zhao, Z. Yang, X. Wang, X. Zhang, M. Wang, Y. Wang, Q. Mei, and Z. Wang, Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin. Exp. Mol. Med. 44, 633 (2012).
8. H. Li, L. Hui, W. Xu, H. Shen, Q. Chen, L. Long, and X. Zhu, Triptolide modulates the sensitivity of K562/A02 cells to adriamycin by regulating miR-21 expression. Oncology Letters 3, 485 (2012).
9. T. N. Mackenzie, N. Mujumdar, S. Banerjee, V. Sangwan, A. Sarver, S. Vickers, S. Subramanian, and A. K. Saluja, Triptolide induces the expression of miR-142-3p: A negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. Mol. Cancer Ther. 12, 1266 (2013).
10. Q. Liu, Triptolide and its expanding multiple pharmacological functions. Int. Immunopharmacol. 11, 377 (2011).
11. S. W. Park and Y. I. Kim, Triptolide induces apoptosis of PMAtreated THP-1 cells through activation of caspases, inhibition of NFkappaB and activation of MAPKs. Int. J. Oncol. 43, 1169 (2013).
12. X. Xue, L. Gong, X. Qi, Y. Wu, G. Xing, J. Yao, Y. Luan, Y. Xiao, Y. Li, X. Wu, M. Chen, J. Gu, and J. Ren, Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity. Toxicol Lett. 205, 47 (2011).
13. L. Liu, Z. Jiang, J. Liu, X. Huang, T. Wang, Y. Zhang, Z. Zhou, J. Guo, L. Yang, Y. Chen, and L. Zhang, Sex differences in subacute toxicity and hepatic microsomal metabolism of triptolide in rats. Toxicology 271, 57 (2010).
14. A. G. Wilson, A. C. White, and R. A. Mueller, Role of predictive metabolism and toxicity modeling in drug discovery-A summary of some recent advancements. Curr. Opin. Drug Discov. Devel. 6, 123 (2003).
15. H. Maeda, The link between infection and cancer: Tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. Cancer Sci. 104, 779 (2013).
16. F. Greco and M. J. Vicent, Polymer-drug conjugates: Current status and future trends. Front Biosci. 13, 2744 (2008).
17. S. Mazzaferro, K. Bouchemal, A. Maksimenko, R. Skanji, P. Opolon, and G. Ponchel, Reduced intestinal toxicity of docetaxel loaded into mucoadhesive nanoparticles, in mouse xenograft model. J. Colloid Sci. Biotechnol. 1, 210 (2012).
18. S Rajaram, P Bhujbal, I. J. Slipper, E. M. Favretto, and D. Douroumis, Prostate cancer targeting with 7E11-C5.3-CdS bioconjugated quantum dots. J. Colloid Sci. Biotechnol. 2, 34 (2013).
19. K. B. Ferenz, I. N. Waack, C. Mayer, H. de Groot, and M. Kirsch, Long-circulating poly(ethylene glycol)-coated poly(lactid-co-glycolid) microcapsules as potential carriers for intravenously administered drugs. J. Microencapsul. 30, 632 (2013).
20. M. L. Immordino, F. Dosio, and L. Cattel, Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 1, 297 (2006).
21. C. Wang, C. Long, C. Xie, X. Chen, L. Zhang, B. Chu, Y. Wang, F. Luo, and Z. Qian, Two novel nanoscale preparations of micelle and thermosensitive hydrogel for docetaxel to treat malignant tumor. J. Biomed. Nanotechnol. 9, 357 (2013).
22. C. Wang, J. Liang, X. Deng, C. Long, C. Xie, X. Chen, L. Zhang, Q. Guo, Y. Wang, F. Luo, and Z. Qian, Synthesis, characterization, and application of amino-terminated poly(ethylene glycol)-blockpoly( epsilon -caprolactone) copolymer for paclitaxel. J. Nanosci. Nanotechnol. 13, 68 (2013).
23. C. Wang, Y. Wang, M. Fan, F. Luo, and Z. Qian, Characterization, pharmacokinetics and disposition of novel nanoscale preparations of paclitaxel. Int. J. Pharm. 414, 251 (2011).
24. C. Gong, C. Wang, Y. Wang, Q. Wu, D. Zhang, F. Luo, and Z. Qian, Efficient inhibition of colorectal peritoneal carcinomatosis by drug loaded micelles in thermosensitive hydrogel composites. Nanoscale 4, 3095 (2012).
25. N. Lei, C. Gong, Z. Qian, F. Luo, C. Wang, H. Wang, and Y. Wei, Therapeutic application of injectable thermosensitive hydrogel in preventing local breast cancer recurrence and improving incision wound healing in a mouse model. Nanoscale 4, 5686 (2012).
26. D. Cejka, M. Preusser, A. Woehrer, W. Sieghart, S. Strommer, J. Werzowa, T. Fuereder, and V. Wacheck, Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol. Ther. 7, 1377 (2008).
27. Y. Hamano, H. Sugimoto, M. A. Soubasakos, M. Kieran, B. R. Olsen, J. Lawler, A. Sudhakar, and R. Kalluri, Thrombospondin- 1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 64, 1570 (2004).
28. J. Du, X. Lu, Z. Long, Z. Zhang, X. Zhu, Y. Yang, and J. Xu, In vitro and in vivo anticancer activity of aconitine on melanoma cell line B16.Molecules 18, 757 (2013).
29. L. Xu, H. Chen, H. Xu, and X. Yang, Anti-tumour and immunomodulation effects of triptolide-loaded polymeric micelles. Eur. J. Pharm. Biopharm. 70, 741 (2008).
30. M. El Filali, G. S. Missotten, W. Maat, L. V. Ly, G. P. Luyten, P. A. van der Velden, and M. J. Jager, Regulation of VEGF-A in uveal melanoma. Invest Ophthalmol. Vis. Sci. 51, 2329 (2010).
31. K. J. Livak and T. D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402 (2001).
32. M. K. Danquah, X. A. Zhang, and R. I. Mahato, Extravasation of polymeric nanomedicines across tumor vasculature. Adv. Drug Deliv. Rev. 63, 623 (2011).
33. T. Lammers, W. E. Hennink, and G. Storm, Tumour-targeted nanomedicines: Principles and practice. Br. J. Cancer 99, 392 (2008).
34. M. S. Shim and Y. J. Kwon, Efficient and targeted delivery of siRNA in vivo. FEBS J. 277, 4814 (2010).
35. W. Zhu, Y. Ou, Y. Li, R. Xiao, M. Shu, Y. Zhou, J. Xie, S. He, P. Qiu, and G. Yan, A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol. Pharmacol. 75, 812 (2009).
36. D. Borja-Cacho, Y. Yokoyama, R. K. Chugh, N. R. Mujumdar, V. Dudeja, K. A. Clawson, R. K. Dawra, A. K. Saluja, and S. M. Vickers, TRAIL and triptolide: An effective combination that induces apoptosis in pancreatic cancer cells. J. Gastrointest Surg 14, 252 (2010).
37. L. Xu, Y. Qiu, H. Xu, W. Ao, W. Lam, and X. Yang, Acute and subacute toxicity studies on triptolide and triptolide-loaded polymeric micelles following intravenous administration in rodents. Food Chem. Toxicol. 57, 371 (2013).
38. H. Li, X. S. Wen, and W. Di, In vitro and in vivo evaluation of Triptolide-loaded pluronic P105 polymeric micelles. Arzneimittelforschung 62, 340 (2012).
39. S. Zheng, K. Löw, S. Wagner, S. Wagner, X. Yang, H. von Briesen, and S. Zou, Cytotoxicity of triptolide and triptolide loaded polymeric micelles in vitro. Toxicol. In Vitro 25, 1557 (2011).